If you're worried about having enough passive income to maintain your lifestyle during retirement, you're not alone. Having to spend more just to maintain their current standard of living is a constant concern for most families.
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
Eli Lilly, J&J, AbbVie, AstraZeneca and Pfizer are included in this Analyst Blog.
AbbVie (ABBV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
Only 11 Dividend Kings outperformed the S&P 500 during the last decade based on Total Return. 5 Dividend Kings earn the rank of "High Quality" based on my custom quantitative model. Using a variation of a truncated custom quality score could have generated a total return nearly double that of the S&P 500 during the last 9 years.
If you're looking for attractive dividend-paying stocks, that's a smart move. If you're not, perhaps reconsider -- because:
In the latest trading session, AbbVie (ABBV) closed at $180, marking a +0.9% move from the previous day.
2024 is going out with a bang as mystery drones, Federal Reserve hawkishness, and quantum stocks dominate headlines. It's time to look towards 2025 after another banner year for stocks. Here are four stocks in timely, tremendous industries to keep on your radar.
With its shares offering a total return of nearly 49% over the last three years, trumping the market's return of 33%, AbbVie (ABBV 2.37%) is a powerhouse big pharma that has a lot of upside to offer to investors.
AbbVie (ABBV 2.37%) and Amgen (AMGN 0.84%) have a lot in common. They are both leading drugmakers and have strong dividend track records.